Triple
T22573060
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Turnitin |
E544323
|
entity |
| Predicate | foundedBy |
P104
|
FINISHED |
| Object | iParadigms |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: iParadigms | Statement: [Turnitin, foundedBy, iParadigms]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: iParadigms Context triple: [Turnitin, foundedBy, iParadigms]
-
A.
Innosight
Innosight is a strategy and innovation consulting firm co-founded by disruptive innovation theorist Clayton Christensen, known for helping organizations navigate transformational growth and change.
-
B.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
C.
Idealab
Idealab is a pioneering technology incubator and startup studio known for launching and nurturing numerous innovative companies across the internet, software, and clean energy sectors.
-
D.
Omada Health
Omada Health is a digital health company that delivers evidence-based, virtual care programs to help people prevent and manage chronic conditions such as diabetes, hypertension, and obesity.
-
E.
Idun Pharmaceuticals
Idun Pharmaceuticals is a biotechnology company focused on developing therapies that regulate cell death pathways, particularly apoptosis, for the treatment of various diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: iParadigms Target entity description: iParadigms is the company behind the Turnitin plagiarism-detection and academic integrity software widely used in educational institutions.
-
A.
Innosight
Innosight is a strategy and innovation consulting firm co-founded by disruptive innovation theorist Clayton Christensen, known for helping organizations navigate transformational growth and change.
-
B.
Innogen
Innogen is the original name of Imogen, the virtuous and wronged heroine of William Shakespeare’s play "Cymbeline."
-
C.
Idealab
Idealab is a pioneering technology incubator and startup studio known for launching and nurturing numerous innovative companies across the internet, software, and clean energy sectors.
-
D.
Omada Health
Omada Health is a digital health company that delivers evidence-based, virtual care programs to help people prevent and manage chronic conditions such as diabetes, hypertension, and obesity.
-
E.
Idun Pharmaceuticals
Idun Pharmaceuticals is a biotechnology company focused on developing therapies that regulate cell death pathways, particularly apoptosis, for the treatment of various diseases.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e11e30d05481909df915354c89f0d6 |
completed | April 16, 2026, 5:36 p.m. |
| NER | Named-entity recognition | batch_69f15fea683c81908fbf9f171eed3341 |
completed | April 29, 2026, 1:33 a.m. |
Created at: April 16, 2026, 8:53 p.m.